Arkolith/Insider Trading/ALGS/Form 4

McClure Matthew W.

Chief Medical OfficerAligos Therapeutics, Inc. (ALGS) · full profile →Form 4 · filed Feb 28, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
0 non-derivative · 6 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 28, 2024Grant(A)66K—$066K
Feb 28, 2024Grant(A)16K—$016K
Feb 28, 2024Grant(A)75K—$075K
Feb 27, 2024Disposed to issuer(D)256K—$00
Feb 27, 2024Disposed to issuer(D)23K—$00
Feb 27, 2024Disposed to issuer(D)92K—$00

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-24-000100) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Aligos Therapeutics, Inc.

Build

Ask your agent about ALGS insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001610717-24-000100"
Ask your agent
Use Arkolith to summarize insider buying and selling at Aligos Therapeutics, Inc.
over the last 90 days and cite the filings.